BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Precigen\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Precigen\, Inc's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07901738-10975@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Papzimeos (Zopapogene imadenovec): Phase 3 readout est. (NCT0790173
 8)
DESCRIPTION:Papzimeos (Zopapogene imadenovec)\, phase 3\, Recurrent Respira
 tory Papillomatosis.\nStudy: Zopapogene Imadenovec for the Treatment of Re
 current Respiratory Papillomatosis in Children\nEstimated primary completi
 on: January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zop
 apogene-imadenovec#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07901738
URL:https://assetmemo.bio/drug/zopapogene-imadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
